Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 9/20 | 0.32 |
| ▸ | RAF1 | P04049 | 5/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862769 | 1.00 | WRN (0.46) | WRNBRAFRAF1PIK3CDPIK3C2B | |
| SCHEMBL30862751 | 1.00 | WRN (0.46) | WRNBRAFRAF1PIK3CDPIK3C2B | |
| SCHEMBL30862724 | 1.00 | WRN (0.46) | WRNBRAFRAF1PIK3CDPIK3C2B | |
| SCHEMBL30862805 | 0.94 | WRN (0.51) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862871 | 0.94 | WRN (0.51) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862732 | 0.94 | WRN (0.51) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862747 | 0.94 | WRN (0.51) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862695 | 0.90 | WRN (0.47) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862843 | 0.90 | WRN (0.47) | WRNBRAFRAF1BTKFLT3 | |
| SCHEMBL30862748 | 0.89 | WRN (0.47) | WRNBRAFRAF1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-07-25 | — | — | US | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245694-A1 | Tricyclic Compounds and their Uses | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | WRN 2992/4885BRAF 2474/4885RAF1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.